How Masteron Affects HDL Cholesterol

Drostanolone propionate is an injectable, non-17-alpha-alkylated dihydrotestosterone derivative. Those structural features place it between the benign injectables and the destructive orals:

1. Injectable, so no first-pass hepatic loading: The propionate ester is cleaved in tissue and drostanolone reaches the liver at systemic concentrations rather than as a portal bolus. Thompson (1989, PMID 2915439) established that this route difference is the dominant determinant of androgen lipid damage: oral stanozolol raised hepatic lipase activity 123% while intramuscular testosterone produced a 25% rise that was not statistically significant.

2. Not 17-alpha-alkylated: There is no alkyl group forcing the molecule to survive hepatic metabolism, so the sustained hepatocyte androgen signal that oral steroids produce is absent.

3. No aromatisation, and this is where masteron loses ground: Drostanolone is a DHT derivative and does not convert to oestradiol. Oestradiol suppresses hepatic lipase gene expression, and Zmuda (1993, PMID 8487666) demonstrated the size of that protection by removing it: adding an aromatase inhibitor to testosterone worsened the HDL fall from 16% to 20%, the apoA-I fall from 12% to 15%, and increased hepatic lipase activity 38% rather than 21%. Masteron never has that protection available.

4. The usage context: masteron is a cutting and hardening compound, almost always stacked on top of a testosterone base and frequently alongside trenbolone or an oral. Its independent contribution to a deteriorated HDL is difficult to isolate in practice and has never been isolated in a trial.

The evidence gap, stated plainly: drostanolone has no human lipid data. Its clinical use was in advanced breast carcinoma in the 1960s and 1970s, before modern lipoprotein methods, and it has never been studied at the doses used in bodybuilding.

There is no measured figure for drostanolone. Any specific percentage attributed to masteron's effect on HDL is invented.

What the class evidence supports:

• Injectable non-alkylated androgens suppress HDL moderately. Sattler (2002, PMID 12388173) measured HDL falling 8.7 to 10.6 mg/dL on high-dose nandrolone over 12 weeks, and Thompson (1989, PMID 2915439) measured a 9% fall on 200 mg/week of testosterone.
• Non-aromatising compounds should sit at the worse end of that range, because they lack the oestradiol-mediated suppression of hepatic lipase.
• Oral 17-alpha-alkylated compounds are in a different category entirely, with stanozolol suppressing HDL 33% at 6 mg/day.

Practical expectation at typical doses (300-600 mg/week):

• HDL falling 20 to 40% is a reasonable working estimate, placing masteron between testosterone and trenbolone in severity.
• Because masteron is a cutting compound, it is usually run alongside a calorie deficit and often alongside diuretics near a contest, both of which independently affect the lipid panel.

Timing: The propionate ester is short, with injections typically every other day, so steady state is reached within a week and lipid changes are established by week 3 to 4.

Recovery: Fast clearance means the compound is out of your system within days of the last injection. Lipid recovery takes 6 to 12 weeks.

Baseline lipid panel before the cycle, not before the masteron. Masteron is almost never the first compound in a stack, so a panel taken partway through will not isolate its contribution.

On cycle:

• Check at week 4. The short ester reaches steady state quickly.
• Track the LDL to HDL ratio and non-HDL cholesterol rather than HDL in isolation.

Contest prep context:

• Masteron use peaks in the final weeks of contest prep, alongside very low body fat, aggressive dieting and sometimes diuretics. All of those affect lipids independently.
• An HDL below 0.8 mmol/L (roughly 30 mg/dL) in the last weeks of prep is common and is a combined effect, not attributable to any one compound.

Post-cycle: Recheck at 8 weeks after the last injection.

Because this compound is unstudied, your own serial bloodwork is the only data available. That is a reason to test more often, not less.

Do not stack masteron with an aromatase inhibitor without reason:

• Masteron contributes no oestradiol of its own, and the oestradiol in a masteron plus testosterone cycle comes entirely from the testosterone. That oestradiol is the only hepatic lipase protection in the protocol. Suppressing it removes the last defence.
• The widely repeated claim that masteron itself has anti-oestrogenic activity is not established in humans and should not be used as a reason to add or remove an aromatase inhibitor.

Compound selection:

• If HDL is the concern, the oral in the stack is a bigger lever than the masteron.
• Keeping the total number of non-aromatising compounds in a stack low limits the cumulative hepatic lipase signal.

Supportive measures:

• Cardiovascular exercise 30 to 45 minutes, 4 to 5 times per week. This is the single most effective non-drug intervention for HDL specifically and it works through a pathway androgens do not touch.
• Omega-3 at 3 to 4 g/day EPA and DHA for triglycerides.
• Citrus bergamot 500 to 1000 mg/day as a small adjunct with modest human evidence, none of it in androgen users.

Further reading: Cholesterol supplements on cycle, ranked by evidence